- Global Pharma News & Resources

Adrenoleukodystrophy Drugs Market Size and Share to Project Lucrative CAGR By 2027 | Future Growth Trends, Key Players Profile, Business Insights, Overview, Growth Projection and Global Market Analysis By 2020

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Adrenoleukodystrophy (ALD) is a rare genetic disorder linked with the X chromosome in males and females. Adrenoleukodystrophy (ALD) causes mutation of the ABCD1 gene in individuals which elevates ALD proteins. These proteins are used to clear toxic molecules known as saturated very long chain fatty acids.  Thus accumulation of saturated very long chain fatty acid in tissue throughout the body leads to damage of myelin, thus causing neurological problems in patients.

Request FREE Sample

Adrenoleukodystrophy (ALD) is most commonly observed in childhood and present in both males and females. Adrenoleukodystrophy (ALD) is further identified by its phenotypes such as childhood onset of ALD, Addison disease, adrenomyeloneuropathy and diagnosed with the help of blood testing, magnetic resonance imaging, vision screening, skin biopsy and fibroblast cell culture. Treatment used for Adrenoleukodystrophy (ALD) are stem cell transplant, adrenal insufficiency treatment, gene therapy and dietary therapy.

Global Adrenoleukodystrophy Drugs Market: Drivers

Adrenoleukodystrophy is a rare genetic disorder which is characterized by symptoms such as childhood onset of ALD, Addison disease, and adrenomyeloneuropathy. Therefore, depending upon symptoms, the type of an adrenoleukodystrophy drug have to be evaluated and  treatment need to be prescribed accordingly. For instance, in May 2020, SwanBio Therapeutics, a developer of biological therapeutics, announced that they have raised US$ 52 million for advancement of their viral base gene therapy for adrenomyeloneuropathy. Funds were raised with the help of series A financing round. These factors are expected to drive growth of the global adrenoleukodystrophy drugs market.

Global Adrenoleukodystrophy Drugs Market: COVID-19 Impact Analysis

COVID-19 has affected several markets around the world. In case of global adrenoleukodystrophy drugs market, adrenoleukodystrophy patients are facing challenges due to reallocation of neurological intensive beds and neurological wards to COVID-19 patients. As a result, there is difficulty in management of emergencies related to neurological disorders. Furthermore, implementation of lockdowns and restrictions on transportation by governments of various countries have affected the supply chain activities, and led to a shortage in inventories of pharmaceutical companies.

Apply Promo Code “STAYHOME” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @

Global Adrenoleukodystrophy Drugs Market: Restraints

Stem cell transplant is a treatment used for Adrenoleukodystrophy but causes side effects such as interstitial pneumonia, liver damage, and mucositis. Moreover, in adrenal insufficiency treatment, hydrocortisone is a major drug which affects cortisol levels in adrenoleukodystrophy patients and also weakens the immune system. Furthermore, gene therapy may lead to mutation of cells and inflammation due to wrong incorporation of DNA on DNA locations. These factors are expected to restrain the global adrenoleukodystrophy drugs market growth.

Global Adrenoleukodystrophy Drugs Market Regional Analysis

On basis of regions, the global Adrenoleukodystrophy market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. In North America, pharmaceutical companies are focusing on advancement of therapies for treatment of adrenoleukodystrophy. For instance, in 2019, Magneta Therapeutics received approval for MGTA-456 regenerative medicine advance therapy designation for treatment of adrenoleukodystrophy from the U.S Food Drug and Administration.

In 2018, Europe PMC claimed that adrenal insufficiency is a life threating condition with mortality rate of 0.5 in 100 patients per year. Moreover, pharmaceutical companies are focusing on research and development of treatments for adrenoleukodystrophy to strengthen their share in the global adrenoleukodystrophy drugs market. For instance, in January 2020, Minoryx Therapeutics, a company specialised in innovation of drugs for central nervous system conditions, received an approval for lead drug candidate, leriglitazone (MIN-102), for treatment of all forms of x- adrenoleukodystrophy.

Special Requirements?
We value your investment and offer customization as per your requirements.

Share your precise requirements @

Global Adrenoleukodystrophy Drugs Market: Key Players

Key operating players in global adrenoleukodystrophy drugs market are Applied Genetic Technologies Corporation, MedDay SA, Bluebird bio, Inc., Minoryx Therapeutics S.L, ReceptoPharm Inc., Pfizer Inc., SOM Innovation Biotech, S.A, SwanBio Therapeutics, and Viking Therapeutics, Inc.

Market Taxonomy:

On the Basis of Treatment, the global adrenoleukodystrophy drugs market is segmented into:

  • Adrenal Insufficiency Treatment
  • Gene Therapy Drugs
  • Dietary Supplements

On the Basis of Patient Type, the global adrenoleukodystrophy drugs market is segmented into:

  • Adult
  • Pediatrics

On the Basis of Distribution Channel, the global adrenoleukodystrophy drugs market is segmented into:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

On the Basis of Indication, the Global Adrenoleukodystrophy Drugs Market is segmented into:

  • Childhood Adrenoleukodystrophy
  • Addison Disease
  • Adrenomyeloneuropathy

On the basis of region, the global adrenoleukodystrophy drugs market is segmented into:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa

Other Related Reports:

HIV-Associated Lipodystrophy Treatment Market, by Lipodystrophy Type (Lipoatrophy and Lipoaccumulation), By Therapeutic class (Anabolism Modulators, Insulin Resistance Modulators, Mitochondrial Antioxidants (l-carnitine), and Other), By Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) and by Geography – Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

Point-of-Care (POC) Infectious Disease Diagnostics Market, by Technology (Lateral Flow, Agglutination Assays, Flow-Through, and Solid Phase), By Application (HIV, Tropical Disease, Liver Disease, Inflammatory Disease, Respiratory Disease, Hospital Associated Infections (HAIs), Sexual Health Disorders, and Others), By End User (Hospitals, Diagnostic Laboratories, Home-Care Settings, and Others), and Region – Global Industry Insights, and Forecast till 2025

Lentiviral Vectors Market, By Product Type (1st-generation, 2nd-generation, and 3rd-generation), By Indication (HIV, β-thalassemia, X-linked Adrenoleukodystrophy, Metachromatic Leukodystrophy, and Wiskott-Aldrich Syndrome), By End User (Hospitals, Clinics, and Research Institutes), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Size, Share Outlook, and Opportunity Analysis, 2020 – 2027

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website –


Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at

Editor Details

  • Company:
    • CDN Newswire
Last Updated: 06-Nov-2020